Effect of Lavender in treatment of depression in diabetic patients

Evaluation of Lavandula angustifolia efficacy in treatment of depression in diabetic patients of Shiraz

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150309021386N2

Enrollment

Registered

2018-07-15

Start date

2018-06-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Depression. Condition 2: Diabetes Mellitus. Condition 3: Diabetes Mellitus. Major Depressive Disorder, single episode, moderate Type 2 Diabetes Mellitus Type 1 Diabetes Mellitus

Interventions

Intervention 1: Intervention group: Sertraline capsule qhs with dosage of 50 mg for 1 week and then 100 mg till the end of the study plus one gelatin capsule containing 200mg of lavender essential oil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 1 or 2 diabetes mellitus that is controlled (70 <FBS <130 and 2hppG <180) • Age over 18 years old• Over 3-months history of depression based on Beck's questionnaire • Satisfaction with participating in the study • No usage of out-of-study protocol treatments (all anti-depressant drugs (TCA, SSRI, SNRI, etc.) and medicinal herbs affecting mood such as bell peppermint, valerian fever, and lemon balm, etc.) • Patients who have mild to moderate depression based on the Beck criteria (score less than 28)

Exclusion criteria

Exclusion criteria: Pregnancy, Lactation, Systemic unstable diseases (liver, thyroid, cardiovascular, renal dx), Active suicidal thoughts

Design outcomes

Primary

Measure	Time frame
Change in Beck Depression Inventory Score. Timepoint: At The Beginning And at The End of The Study. Method of measurement: Beck Depression Questionnaire.	—

Secondary

Measure	Time frame
Pittsburgh Insomnia Questionnaire. Timepoint: At The Beginning and at The End of The Study. Method of measurement: Pittsburgh Insomnia Questionnaire.;Change of WHO-5 Well-being Index Questionnaire Score. Timepoint: At The Beginning and at The End of The Study. Method of measurement: WHO-5 Well-being Index Questionnaire.;Change of Biochemical Variables. Timepoint: At The Beginning and at The End of The Study. Method of measurement: Laboratory Data.	—

Measure

Time frame

Pittsburgh Insomnia Questionnaire. Timepoint: At The Beginning and at The End of The Study. Method of measurement: Pittsburgh Insomnia Questionnaire.;Change of WHO-5 Well-being Index Questionnaire Score. Timepoint: At The Beginning and at The End of The Study. Method of measurement: WHO-5 Well-being Index Questionnaire.;Change of Biochemical Variables. Timepoint: At The Beginning and at The End of The Study. Method of measurement: Laboratory Data.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohadese? Ostovar

Shiraz University of Medical Sciences

ostovarm@sums.ac.ir+98 71 3230 5886

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026